Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1 Active not recruiting 278 enrolled M.D. Anderson Cancer Center

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combinations will also be studied.

Timeline

Start: 2010-08-19
Primary completion: 2026-04-30
Completion: 2026-04-30

Publications

Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, Ross JS, Stephens PJ, Palmer GA, Ali SM. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol. 2014 Jan 14;7:8. doi: 10.1186/1756-8722-7-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	—
Subject	Carboplatin	Small molecule	2 unknown	—
Subject	Paclitaxel	Small molecule	30 mg/m2	—
Subject	Sorafenib	Small molecule	200 mg	—
Subject	Temsirolimus	Small molecule	12.5 mg	—

Indications

No indication recorded.